Impact of Postmastectomy Radiation Therapy on Breast Cancer Patients According to Pathologic Nodal Status after Modern Neoadjuvant Chemotherapy
4
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The utility of postmastectomy radiation therapy (PMRT) for breast cancer patients after neoadjuvant chemotherapy (NAC) is highly controversial. This study evaluated the impact of PMRT according to pathologic nodal status after modern NAC. Materials and Methods We retrospectively reviewed 682 patients with clinical stage II-III breast cancer who underwent NAC and mastectomy from 2013 to 2017. In total, 596 patients (87.4%) received PMRT, and 86 (12.6%) did not. We investigated the relationships among locoregional recurrence-free survival (LRRFS), disease-free survival (DFS), overall survival (OS), and various prognostic factors. Subgroup analyses were also performed to identify patients who may benefit from PMRT. Results The median follow-up duration was 67 months. In ypN+ patients (n=368, 51.2%), PMRT showed significant benefits in terms of LRRFS, DFS, and OS (all p < 0.001). In multivariate analyses, histologic grade (HG) III (p=0.002), lymphovascular invasion (LVI) (p=0.045), and ypN2-3 (p=0.02) were significant risk factors for poor LRRFS. In ypN1 patients with more than two prognostic factors among luminal/human epidermal growth factor receptor-2–negative subtype, HG I-II, and absence of LVI, PMRT had no significant effect on LRRFS (p=0.18). In ypN0 patients (n=351, 48.8%), PMRT was not significantly associated with LRRFS, DFS, or OS. However, PMRT showed better LRRFS in triple-negative breast cancer (TNBC) patients (p=0.03). Conclusion PMRT had a major impact on treatment outcomes in patients with residual lymph nodes following NAC and mastectomy. Among ypN0 patients, PMRT may be beneficial only for those with TNBC.
Abstract
Purpose The utility of postmastectomy radiation therapy (PMRT) for breast cancer patients after neoadjuvant chemotherapy (NAC) is highly controversial. This study evaluated the impact of PMRT according to pathologic nodal status after modern NAC. Materials and Methods We retrospectively reviewed 682 patients with clinical stage II-III breast cancer who underwent NAC and mastectomy from 2013 to 2017. In total, 596 patients (87.4%) received PMRT, and 86 (12.6%) did not. We investigated the relationships among locoregional recurrence-free survival (LRRFS), disease-free survival (DFS), overall survival (OS), and various prognostic factors. Subgroup analyses were also performed to identify patients who may benefit from PMRT. Results The median follow-up duration was 67 months. In ypN+ patients (n=368, 51.2%), PMRT showed significant benefits in terms of LRRFS, DFS, and OS (all p < 0.001). In multivariate analyses, histologic grade (HG) III (p=0.002), lymphovascular invasion (LVI) (p=0.045), and ypN2-3 (p=0.02) were significant risk factors for poor LRRFS. In ypN1 patients with more than two prognostic factors among luminal/human epidermal growth factor receptor-2–negative subtype, HG I-II, and absence of LVI, PMRT had no significant effect on LRRFS (p=0.18). In ypN0 patients (n=351, 48.8%), PMRT was not significantly associated with LRRFS, DFS, or OS. However, PMRT showed better LRRFS in triple-negative breast cancer (TNBC) patients (p=0.03). Conclusion PMRT had a major impact on treatment outcomes in patients with residual lymph nodes following NAC and mastectomy. Among ypN0 patients, PMRT may be beneficial only for those with TNBC.
참고문헌 (30)
- Gralow JR, "Preoperative therapy in invasive breast cancer : pathologic assessment and systemic therapy issues in operable disease", J Clin Oncol, 26, pp.814~819 (2008)
- Mougalian SS, "Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States", Cancer, 121, pp.2544~2552 (2015)
- Fisher B, "Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer : findings from National Surgical Adjuvant Breast and Bowel Project B-18", J Clin Oncol, 15, pp.2483~2493 (1997)
- Kaufmann M, "Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer", Ann Surg Oncol, 19, pp.1508~1516 (2012)
- Gianni L, "5-Year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer(NeoSphere) : a multicentre, open-label, phase 2 randomised trial", Lancet Oncol, 17, pp.791~800 (2016)
- Sevcikova K, "Neoadjuvant treatment in patients with HER2-positive breast cancer", ISRN Oncol, 2013, pp.362467~ (2013)
- Harris EE, "The impact of the size of nodal metastases on recurrence risk in breast cancer patients with 1-3 positive axillary nodes after mastectomy", Int J Radiat Oncol Biol Phys, 85, pp.609~614 (2013)
- Early Breast Cancer Trialists’ Collaborative Group, "Effect of radiotherapy after breast-conserving surgery on 10-year recu-rrence and 15-year breast cancer death : meta-analysis of individual patient data for 10, 801 women in 17 randomised trials", Lancet, 378, pp.1707~1716 (2011)
- Macdonald S, "Breast cancer breast cancer", J R Soc Med, 70, pp.515~517 (2016)
- Zhang Y, "Impact of postmastectomy radiotherapy on locoregional control and disease-free survival in patients with breast cancer treated with neoadjuvant chemotherapy", J Oncol, 2021, pp.6632635~ (2021)
- Ohri N, "Postmastectomy radiation in breast cancer patients with pathologically positive lymph nodes after neoadjuvant chemotherapy : usage rates and survival trends", Int J Radiat Oncol Biol Phys, 99, pp.549~559 (2017)
- Mamounas EP, "Predictors of locoregional recurrence after neoadjuvant chemotherapy : results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27", J Clin Oncol, 30, pp.3960~3966 (2012)
- Shim SJ, "The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0 : a multicenter, retrospective study(KROG 12-05)", Int J Radiat Oncol Biol Phys, 88, pp.65~72 (2014)
- 조원경, "The Benefit of Post-Mastectomy Radiotherapy in ypN0 Patients after Neoadjuvant Chemotherapy According to Molecular Subtypes", Journal of Breast Cancer, 22(2), pp.285~296 (2019), 한국유방암학회[DOI]
- Le Scodan R, "Radiotherapy for stage II and stage III breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy", Int J Radiat Oncol Biol Phys, 82, pp.e1~7 (2012)
- Zhang J, "Effect of pathologic stages on postmastectomy radiation therapy in breast cancer receiving neoadjuvant chemotherapy and total mastectomy : a cancer database analysis", Breast, 54, pp.70~78 (2020)
- Wang K, "The role of postmastectomy radiation in patients with ypN0 breast cancer after neoadjuvant chemotherapy : a meta-analysis", BMC Cancer, 21, pp.728~ (2021)
- 장범섭, "Postmastectomy Radiation Therapy in Patients With Minimally Involved Lymph Nodes: A Review of the Current Data and Future Directions", Journal of Breast Cancer, 25(1), pp.1~12 (2022), 한국유방암학회[DOI]
- Miyashita M, "Role of postmastectomy radiotherapy after neoadjuvant chemotherapy in breast cancer patients : a study from the Japanese Breast Cancer Registry", Ann Surg Oncol, 26, pp.2475~2485 (2019)
- Rastogi P, "Preoperative chemotherapy : updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27", J Clin Oncol, 26, pp.778~785 (2008)
- Haque W, "Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy", Breast Cancer Res Treat, 170, pp.559~567 (2018)
- Berruti A, "Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy : a meta-regression of 29 randomized prospective studies", J Clin Oncol, 32, pp.3883~3891 (2014)
- Spring LM, "Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival : a comprehensive meta-analysis", Clin Cancer Res, 26, pp.2838~2848 (2020)
- Sestak I, "Factors predicting late recurrence for estrogen receptor-positive breast cancer", J Natl Cancer Inst, 105, pp.1504~1511 (2013)
- Blows FM, "Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival : a collaborative analysis of data for 10, 159 cases from 12 studies", PLoS Med, 7, pp.e1000279~ (2010)
- Huang Z, "Postmastectomy radiation therapy based on pathologic nodal status in clinical node-positive stage II to III breast cancer treated with neoadjuvant chemotherapy", Int J Radiat Oncol Biol Phys, 108, pp.1030~1039 (2020)
- Lee J, "The impact of post-mastectomy radiotherapy on survival outcomes in breast cancer patients who underwent neoadjuvant chemotherapy", Cancers (Basel), 13, pp.6205~ (2021)
- Wright JL, "Predictors of locoregional outcome in patients receiving neoadjuvant therapy and postmastectomy radiation", Cancer, 119, pp.16~25 (2013)
- Jeon SH, "Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy", Breast Cancer Res Treat, 172, pp.619~626 (2018)
- Fowble B, "Indications for postmastectomy radiation after neoadjuvant chemotherapy in ypN0 and ypN1-3 axillary node-positive women", Clin Breast Cancer, 18, pp.e107~13 (2018)